Everyone experiences nosebleeds at some point, but nosebleeds with no known cause can be a sign of hemophilia, according to ...

December 13, 2011 — Transfer of the factor IX gene into hepatocytes via peripheral vein infusion is effective against hemophilia B, report Amit C. Nathwani, MD, PhD, from University College ...

Standard treatment for hemophilia B involves replacing the missing clotting factor so that the blood can clot properly. This is called factor 9 replacement therapy.

BioMarin's Roctavian gene therapy shows long-term effectiveness in treating severe hemophilia A, reducing bleeding and ...

An experimental Pfizer hemophilia drug that takes a new approach to treating the blood clotting disorder has met the main goal of a pivotal study, setting the stage for regulatory submissions ...

Your blood contains proteins, called clotting factors, that help to control bleeding. Healthcare providers treat hemophilia by boosting clotting factor levels or replacing missing clotting factors.

Hemophilia is a rare blood clotting disorder that can lead to prolonged bleeding after an injury or surgery, as well as spontaneous bleeding in the muscles, joints, or organs.

Hemophilia A and B are perhaps the best-known clotting diseases, ... With HMB-001, Hemab aims to use blood clotting proteins already in the body to help improve platelet function.

WASHINGTON (AP) — U.S. health regulators on Tuesday approved the first gene therapy for hemophilia, a $3.5 million one-time treatment for the blood-clotting disorder. The Food and Drug ...

Hympavzi, made by Pfizer, is the first antitissue-factor pathway inhibitor to be approved for the blood-clotting disorder, as well as the first hemophilia drug to offer a once-weekly treatment ...

TEHRAN – The national week to support individuals with hemophilia will be held from July 23 to 29.

WASHINGTON – U.S. health regulators on Tuesday approved the first gene therapy for hemophilia, a $3.5 million one-time treatment for the blood-clotting disorder.. The Food and Drug ...